Showing results (191-200 of 280) with videos related to
Sort By:
Pageof 28
Leukemia Research|July 6, 2010
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSFB Douglas Smith, Richard J Jones, Eunpi Cho, et al.Cancer Research|October 15, 2009
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignanciesYing Ye, Michael A McDevitt, Mingzhou Guo, et al.British Journal of Haematology|June 13, 2002
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experienceB Douglas Smith, Richard J Jones, Shing M Lee, et al.Cancer Immunology Research|February 19, 2014
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancerKunle Odunsi, Junko Matsuzaki, Smitha R James, et al.Cancer|November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research ConsortiumElias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.Cancer Research Communications|October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.Journal for Immunotherapy of Cancer|October 20, 2020
The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemiaMichael M Boyiadzis, Ivan Aksentijevich, Daniel A Arber, et al.Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.Blood|April 15, 2020
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover studyGuillermo Garcia-Manero, Elizabeth A Griffiths, David P Steensma, et al.JCO Precision Oncology|January 13, 2022
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide TherapyAbhay Singh, Nuria Mencia-Trinchant, Elizabeth A Griffiths, et al.Pageof 28